A Randomized Clinical Trial to Assess the Effects of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability in Healthy Subjects

Trial Profile

A Randomized Clinical Trial to Assess the Effects of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2014

At a glance

  • Drugs MK 2637 (Primary) ; Dextromethorphan
  • Indications Schizophrenia
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 24 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Aug 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 15 Jul 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top